Canada Expansion Theratechnologies has an exclusive Canadian licensing deal with Ionis Pharmaceuticals to commercialize RNA-targeted medicines, creating a clear route for market access, payer negotiations, and specialty pharmacy channels in Canada. This partnership can be paired with a focused sales plan targeting provincial and private payers, clinics, and patient advocacy groups, aligning education and launches with Ionis on roadmap products.

HIV Market Position Theratechnologies markets prescription HIV therapies in the United States and actively shares clinical data at major HIV forums, signaling readiness to engage payers and providers to drive product uptake. The presence of cardiovascular risk data in HIV customers offers a differentiator when communicating safety and care management to clinicians and hospital systems.

Pipeline Synergy With a pipeline spanning HIV, oncology and rare diseases and ongoing preclinical oncology work, Theratechnologies can pursue co-development or strategic alliances to broaden the addressable market beyond HIV, including partnerships with US or Canadian pharma for commercialization of new indications.

Growth Finance Recent financing activities and a mid-sized revenue footprint suggest capacity to fund expanded field teams, market access programs, and early commercial initiatives. This financial moat supports potential BD deals, exclusive distribution arrangements, or co-promotion opportunities with larger biopharma partners.

Conference Momentum Active participation in the ACTHIV conference and the CROI conference, along with data-driven communications, provides a platform to engage key opinion leaders and academic centers. This momentum can be leveraged to schedule early access programs, pilot collaborations, and long-term partnerships with healthcare systems.